OvaScience Inc. (NASDAQ:OVAS) fell 3.4% during trading on Tuesday . The stock traded as low as $6.10 and last traded at $6.22, with a volume of 98,742 shares trading hands. The stock had previously closed at $6.44.

Several research firms have recently commented on OVAS. Leerink Swann reissued a “hold” rating and issued a $7.00 target price (up from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. JPMorgan Chase & Co. lowered their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 5th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, August 10th. JMP Securities reissued a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Finally, Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $10.98.

The company has a 50 day moving average price of $5.48 and a 200 day moving average price of $7.07. The company’s market capitalization is $217.63 million.

OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.16. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. During the same quarter in the previous year, the company earned ($0.64) earnings per share. The firm’s revenue for the quarter was up 530.0% on a year-over-year basis. Equities analysts anticipate that OvaScience Inc. will post ($2.66) EPS for the current year.

In other OvaScience news, CEO Michelle Dipp bought 425,000 shares of the business’s stock in a transaction on Wednesday, June 1st. The stock was purchased at an average cost of $7.00 per share, for a total transaction of $2,975,000.00. Following the completion of the purchase, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at $6,803,447. The acquisition was disclosed in a filing with the SEC, which is available at this link.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.